Cargando…

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting

CONTEXT: Treatment satisfaction with a loading phase of monthly injections for 3 months followed by a pro-re-nata regimen of ranibizumab in neovascular age-related macular degeneration (nAMD) remains unclear. AIMS: The aim was to evaluate the treatment satisfaction of persons with nAMD treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohil, Rishma, Crosby-Nwaobi, Roxanne, Forbes, Angus, Burton, Ben J, Hykin, Philip, Sivaprasad, Sobha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889099/
https://www.ncbi.nlm.nih.gov/pubmed/27307715
http://dx.doi.org/10.2147/PPA.S105536
_version_ 1782434947022192640
author Gohil, Rishma
Crosby-Nwaobi, Roxanne
Forbes, Angus
Burton, Ben J
Hykin, Philip
Sivaprasad, Sobha
author_facet Gohil, Rishma
Crosby-Nwaobi, Roxanne
Forbes, Angus
Burton, Ben J
Hykin, Philip
Sivaprasad, Sobha
author_sort Gohil, Rishma
collection PubMed
description CONTEXT: Treatment satisfaction with a loading phase of monthly injections for 3 months followed by a pro-re-nata regimen of ranibizumab in neovascular age-related macular degeneration (nAMD) remains unclear. AIMS: The aim was to evaluate the treatment satisfaction of persons with nAMD treated with ranibizumab in a real-life setting. SETTINGS AND DESIGN: A cross-sectional study was conducted across three eye clinics within the National Health Service in the UK, where treatment is provided free at point of contact. MATERIALS AND METHODS: A total of 250 patients were selected randomly for the study. Treatment satisfaction was assessed using the Macular Treatment Satisfaction Questionnaire. Data were collected on satisfaction of the service provided (Client Service Questionnaire-8) and the patients’ demographic and quality of life and treatment history. Factors governing treatment questionnaire were determined. RESULTS: The most important factors that determined the satisfaction were the service provided at the clinic (Client Service Questionnaire-8), health-related quality of life (EQ-5D-3L), and duration of AMD. Visual acuity changes were rated as less important than one would have expected. CONCLUSION: The study result suggested that treatment satisfaction for nAMD was governed by the perception of being reviewed and injected regularly over a long period of time than the actual change in visual acuity from the treatment.
format Online
Article
Text
id pubmed-4889099
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48890992016-06-15 Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting Gohil, Rishma Crosby-Nwaobi, Roxanne Forbes, Angus Burton, Ben J Hykin, Philip Sivaprasad, Sobha Patient Prefer Adherence Original Research CONTEXT: Treatment satisfaction with a loading phase of monthly injections for 3 months followed by a pro-re-nata regimen of ranibizumab in neovascular age-related macular degeneration (nAMD) remains unclear. AIMS: The aim was to evaluate the treatment satisfaction of persons with nAMD treated with ranibizumab in a real-life setting. SETTINGS AND DESIGN: A cross-sectional study was conducted across three eye clinics within the National Health Service in the UK, where treatment is provided free at point of contact. MATERIALS AND METHODS: A total of 250 patients were selected randomly for the study. Treatment satisfaction was assessed using the Macular Treatment Satisfaction Questionnaire. Data were collected on satisfaction of the service provided (Client Service Questionnaire-8) and the patients’ demographic and quality of life and treatment history. Factors governing treatment questionnaire were determined. RESULTS: The most important factors that determined the satisfaction were the service provided at the clinic (Client Service Questionnaire-8), health-related quality of life (EQ-5D-3L), and duration of AMD. Visual acuity changes were rated as less important than one would have expected. CONCLUSION: The study result suggested that treatment satisfaction for nAMD was governed by the perception of being reviewed and injected regularly over a long period of time than the actual change in visual acuity from the treatment. Dove Medical Press 2016-05-26 /pmc/articles/PMC4889099/ /pubmed/27307715 http://dx.doi.org/10.2147/PPA.S105536 Text en © 2016 Gohil et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Gohil, Rishma
Crosby-Nwaobi, Roxanne
Forbes, Angus
Burton, Ben J
Hykin, Philip
Sivaprasad, Sobha
Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
title Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
title_full Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
title_fullStr Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
title_full_unstemmed Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
title_short Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
title_sort treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889099/
https://www.ncbi.nlm.nih.gov/pubmed/27307715
http://dx.doi.org/10.2147/PPA.S105536
work_keys_str_mv AT gohilrishma treatmentsatisfactionofpatientsundergoingranibizumabtherapyforneovascularagerelatedmaculardegenerationinareallifesetting
AT crosbynwaobiroxanne treatmentsatisfactionofpatientsundergoingranibizumabtherapyforneovascularagerelatedmaculardegenerationinareallifesetting
AT forbesangus treatmentsatisfactionofpatientsundergoingranibizumabtherapyforneovascularagerelatedmaculardegenerationinareallifesetting
AT burtonbenj treatmentsatisfactionofpatientsundergoingranibizumabtherapyforneovascularagerelatedmaculardegenerationinareallifesetting
AT hykinphilip treatmentsatisfactionofpatientsundergoingranibizumabtherapyforneovascularagerelatedmaculardegenerationinareallifesetting
AT sivaprasadsobha treatmentsatisfactionofpatientsundergoingranibizumabtherapyforneovascularagerelatedmaculardegenerationinareallifesetting